- Home
- HLXC vs CRDF Comparison
HLXC vs CRDF Comparison
Compare HLXC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$1.57
Company Overview
Basic Information| Metric | HLXC | CRDF |
|---|---|---|
| Founded | 2025 | 1999 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.9M | 187.9M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | HLXC | CRDF |
|---|---|---|
| Price | $10.16 | $1.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 85.0K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $10.13 | $1.48 |
| 52 Week High | $10.35 | $4.99 |
Technical Indicators
Market Signals| Indicator | HLXC | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 32.21 |
| Support Level | $10.16 | $1.53 |
| Resistance Level | $10.29 | $1.68 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 13.64 | 21.43 |
Price Performance
Historical Comparison HLXC
CRDF
About HLXC Helix Acquisition Corp. III Class A Ordinary Shares
Helix Acquisition Corp III is a blank check company.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.